Scholarlink

This case illustrates the acute onset of hyperosmia almost 1 year after the initiation of anti-PD-1 monotherapy. This patient remains in clinical remission without evidence of recurrent melanoma but continues to have persistent symptoms of hyperosmia. Her sensitivity to smell has not improved since cessation of ICI despite different treatments and continues to severely impact her quality of life.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyperosmia Secondary to Immune Checkpoint Inhibitor Therapy

  • 章节

  • 发表日期：

    2025年

查看全文
  • Jane M. Taylor,
  • Marcus S. Dempster,
  • Jung-Min Song,
  • Lucy Boyce Kennedy,
  • Pauline Funchain

摘要

This case illustrates the acute onset of hyperosmia almost 1 year after the initiation of anti-PD-1 monotherapy. This patient remains in clinical remission without evidence of recurrent melanoma but continues to have persistent symptoms of hyperosmia. Her sensitivity to smell has not improved since cessation of ICI despite different treatments and continues to severely impact her quality of life.